SAN FRANCISCO, June 13, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical
company, today announced that Chief Executive Officer Thomas B. Neff will participate in a Fireside Chat at the Goldman Sachs 38th
Annual Global Healthcare Conference in Rancho Palos Verdes, California, on Thursday, June 15, at 10:40 a.m. Pacific Time. A live
audio webcast of the presentation will be available under the Investors section of the FibroGen website at www.fibrogen.com. The replay of the webcast will be available for at least 14 days following the
webcast.
About FibroGen, Inc.
FibroGen, Inc., headquartered in San Francisco, CA with subsidiary offices in Beijing and Shanghai, PRC, is a leading
science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company
applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance
innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most advanced product
candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment
of anemia in chronic kidney disease (CKD) and is entering Phase 3 development for anemia in lower risk myelodysplastic syndromes
(MDS). Pamrevlumab, a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is
in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne
muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
Contact FibroGen, Inc. Karen L. Bergman Vice President, Investor Relations and Corporate Communications 1.415.978.1433 kbergman@fibrogen.com
